HansBiomed Corporation (KOSDAQ:042520)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,780.00
-250.00 (-3.56%)
At close: Mar 28, 2025, 3:30 PM KST
-53.27%
Market Cap 88.05B
Revenue (ttm) 80.65B
Net Income (ttm) -8.04B
Shares Out 12.99M
EPS (ttm) -620.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,608
Average Volume 13,075
Open 7,200.00
Previous Close 7,030.00
Day's Range 6,650.00 - 7,440.00
52-Week Range 6,500.00 - 14,970.00
Beta 0.66
RSI 19.04
Earnings Date May 15, 2025

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 261
Stock Exchange KOSDAQ
Ticker Symbol 042520
Full Company Profile

Financial Performance

In 2024, HansBiomed's revenue was 81.14 billion, an increase of 3.98% compared to the previous year's 78.03 billion. Losses were -7.22 billion, -68.66% less than in 2023.

Financial Statements

News

There is no news available yet.